MedTrace Logo

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

NCT05536154 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-03-19

No results posted yet for this study

Summary

This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) as first line mobilization regimen of hematopoietic stem cells in patients with lymphoma and multiple myeloma. All eligible patients will receive EAP regimen treatment, then the number of CD34+ cells and white blood cells will be monitoring. When the collection standard is met, hematopoietic stem cell collection will be started.

Conditions

Interventions

DRUG

Etoposide

Day 1\~Day 2: 75mg/m\^2

DRUG

Cytarabine

Day 1\~Day 2: 200mg/m\^2, q12h

DRUG

PEG-rhG-CSF

Day 6: 6mg

Sponsors & Collaborators

  • The Affiliated People's Hospital of Ningbo University

    lead OTHER_GOV

Principal Investigators

  • Ying Lu · The Affiliated People's Hospital of Ningbo University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2024-06-30
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05536154 on ClinicalTrials.gov